GLS and melanoma: TMZ has been combined with inhibitors that target not only MGMT [15], NF-κB [13], and Notch signaling [39] but also AKT [44], mTOR signaling [45], autophagy [46,47], and glutaminase-mediated glutamine metabolism [48], all of which significantly enhanced TMZ cytotoxicity in melanoma cells.